THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced, for the full year 2017, the company now expects, on a non-GAAP basis, EPS in the range of $12.00 to $12.60. Previously, the company expected non-GAAP EPS in the range of $11.80 to $12.60. Total revenues is expected to be in the range of $22.3 billion to $23.1 billion, unchanged from previous guidance.
For the first-quarter, non-GAAP EPS increased 9 percent to $3.15 driven by higher operating margins. On average, 21 analysts polled by Thomson Reuters expected the company to report profit per share of $3.0 for the quarter. Analysts' estimates typically exclude special items.
First-quarter total revenues decreased 1 percent year-over-year to $5.46 billion. Analysts expected revenue of $5.6 billion for the quarter. Enbrel (etanercept) sales decreased 15 percent due to the impact of competition as well as lower rheumatology and dermatology segment growth compared to prior quarters.
Copyright RTT News/dpa-AFX
© 2017 AFX News
